Aquestive Therapeutics (AQST) Retained Earnings (2018 - 2026)

Aquestive Therapeutics' Retained Earnings history runs 9 years deep, the most recent figure standing at $420.9 million for Q1 2026.

• On a quarterly basis, Retained Earnings rose 29.45% year-over-year to $420.9 million in Q1 2026; TTM through Mar 2026 was $420.9 million, a 29.45% increase from a year earlier, with the FY2025 full-year figure at $413.2 million, up 36.39% from the prior year.
• Retained Earnings rose to $420.9 million in Q1 2026 per AQST's latest filing, from $413.2 million in the prior quarter.
• Across five years, Retained Earnings topped out at $420.9 million in Q1 2026 and bottomed at -$415.1 million in Q3 2025.
• The 5-year median for Retained Earnings is -$286.3 million (2022), against an average of -$39.0 million.
• Across the five-year window, Retained Earnings plunged 271.43% in 2023 and surged 197.95% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$311.2 million in 2022, then dropped by 2.53% to -$319.1 million in 2023, then surged by 194.95% to $303.0 million in 2024, then surged by 36.39% to $413.2 million in 2025, then rose by 1.85% to $420.9 million in 2026.
• Per Business Quant, the three latest AQST Retained Earnings figures stand at $420.9 million (Q1 2026), $413.2 million (Q4 2025), and -$415.1 million (Q3 2025).